investorscraft@gmail.com

Stock Analysis & ValuationShuttle Pharmaceuticals Holdings, Inc. (SHPH)

Previous Close
$0.69
Sector Valuation Confidence Level
High
Valuation methodValue, $Upside, %
Artificial intelligence (AI)n/an/a
Intrinsic value (DCF)n/a
Graham-Dodd Methodn/a
Graham Formulan/a

Company Information

One Research Court
Gaithersburg, MD 20850
United States
Phone: 240 403 4212
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
CEO: Christopher Robert Cooper
Full Time Employees: 9

Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers. The company was founded in 2012 and is based in Rockville, Maryland.

HomeMenuAccount